[Experiences with methyl-benzyl-hydrazine (Natulan) in lymphoreticular diseases and hemoblastoses].
D000744:Anemia, Hemolytic, Autoimmune / Q000188:drug therapy; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D002277:Carcinoma / Q000188:drug therapy; D003093:Colitis, Ulcerative / Q000188:drug therapy; D004802:Eosinophilia / Q000139:chemically induced; D006801:Humans; D006834:Hydrazines / Q000627:therapeutic use*; D007945:Leukemia, Lymphoid / Q000188:drug therapy; D007970:Leukopenia / Q000139:chemically induced; D008214:Lymphocytes / Q000187:drug effects; D008223:Lymphoma / Q000188:drug therapy; D008407:Mast Cells / Q000187:drug effects; D009101:Multiple Myeloma / Q000188:drug therapy; D009404:Nephrotic Syndrome / Q000188:drug therapy; D011087:Polycythemia Vera / Q000188:drug therapy; D013997:Time Factors; D008258:Waldenstrom Macroglobulinemia / Q000188:drug therapy
D006834:Hydrazines
Erfahrungen mit Methyl-benzyl-Hydrazin (Natulan) bei lymphoreticulären Erkrankungen und Hämoblastosen.